G. Tóth

发表

Does Body Mass Index associate with the endoscopic severity of gastroesophageal reflux disease

P. Demeter, Á. Pap, G. Tóth, 2004 .

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

G. Veres, K. Farkas, F. Nagy, 2011, Alimentary pharmacology & therapeutics.

[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].

G. Veres, K. Farkas, F. Nagy, 2011, Orvosi Hetilap.

Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

K. Farkas, T. Molnár, M. Papp, 2016, Journal of Crohn's & colitis.

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort

K. Farkas, F. Nagy, T. Molnár, 2017, Inflammatory bowel diseases.

Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study

W. Reinisch, J. Panés, G. Comer, 2015, Gut.

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.

Teck Kiang Tan, J. Mansfield, Fraser Cummings, 2021, The lancet. Gastroenterology & hepatology.

Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients

P. Ljungman, M. Hassan, G. Avetisyan, 2005, Bone Marrow Transplantation.

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort

K. Farkas, F. Nagy, T. Molnár, 2017, Expert opinion on drug safety.

Final Results on Immunogenicity Profile and Predictors of ADA Development of Biosimilar Infliximab During the First 12 Months of the Therapy: Results from a Prospective Nationwide Cohort

K. Farkas, T. Molnár, M. Papp, 2017 .

P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort.

T. Molnár, M. Papp, P. Lakatos, 2017, Journal of Crohn's & colitis.

P331 Final results on efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort.

F. Nagy, T. Molnár, M. Papp, 2017, Journal of Crohn's & colitis.

Psychometric validation of the Hungarian translation of the gastrointestinal symptom rating scale (GSRS) and quality of life in reflux and dyspepsia (QOLRAD) questionnaire in patients with reflux disease.

I. Wiklund, J. Carlsson, L. Bárány, 2004, Orvosi hetilap.

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.

Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study

W. Reinisch, J. Panés, G. Comer, 2015, Gut.